奥拉帕利靶向治疗卵巢癌含铂二线化疗失败的疗效

The Efficacy of Olaparib in Targeted Treatment of Ovarian Cancer with Failure of Platinum-containing Second-line Chemotherapy

目的分析卵巢癌二线化疗失败后应用奥拉帕利靶向治疗的疗效。方法选取2018年10月1日~2019年12月31日我院收治的含铂二线化疗失败的卵巢癌患者44例作为研究对象,按照随机数字表法分为观察组和对照组,每组22例。对照组予4周期化疗,观察组予口服奥拉帕利靶向治疗,比较两组治疗后3个月近期疗效、糖类抗原CA125变化及不良反应。结果治疗后3个月,观察组总有效率高于对照组(54.55%vs 22.73%),差异有统计学意义(P<0.05)。观察组CA125低于低于对照组[(171.27±162.18)U/ml vs(722.51±680.01)U/ml],差异有统计学意义(P<0.05)。两组骨髓抑制、乏力、胃肠道反应发生率比较,差异无统计学意义(P>0.05);观察组周围神经病变发生率低于对照组,差异有统计学意义(P<0.05)。结论奥拉帕利可作为卵巢癌二线化疗失败后优选的药物,可降低CA125水平及不良反应发生几率,对控制卵巢癌的进展具有良好效果。

Objective To analyze the efficacy of targeted therapy with olaparib after failure of second-line chemotherapy for ovarian cancer.Methods From October 1,2018 to December 31,2019,44 patients with ovarian cancer who failed platinum-containing second-line chemotherapy admitted to our hospital were selected as the research objects.According to the random number table method,they were divided into observation group and control group,each with 22 patient.The control group was given 4 cycles of chemotherapy,and the observation group was given oral olaparib targeted therapy.The short-term efficacy,changes in carbohydrate antigen CA125 and adverse reactions were compared between the two groups at 3 months after treatment.Results After 3 months of treatment,the total effective rate of the observation group was higher than that of the control group(54.55%vs.22.73%),the difference was statistically significant(P<0.05).CA125 in the observation group was lower than that in the control group[(171.27±162.18)U/ml vs(722.51±680.01)U/ml],the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of bone marrow suppression,fatigue,and gastrointestinal reactions between the two groups(P>0.05);The incidence of peripheral neuropathy in the observation group was lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion Olaparib can be used as the preferred drug after failure of second-line chemotherapy for ovarian cancer.It can reduce the level of CA125 and the probability of adverse reactions,and has a good effect on controlling the progression of ovarian cancer.